Huge hepatocellular carcinoma greater than 10 cm in diameter worsens prognosis by causing distant recurrence after curative resection

Wakayama, Kenji; Kamiyama, Toshiya; Yokoo, Hideki; Orimo, Tatsuya; Shimada, Shingo; Einama, Takahiro; Kamachi, Hirofumi; Taketomi, Akinobu

doi:10.1002/jso.24501

Cited by 47 publications

(49 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hepatocellular carcinoma (HCC) is one of the most common malignant tumors, with a poor prognosis and low survival rates [4,5]. Despite advances in the understanding of the molecular mechanisms of HCC, the overall low survival time, high rates of metastasis, postsurgical recurrence, and chemoresistance are still unsolved problems [5][6][7][8].…”

Section: Introductionmentioning

confidence: 99%

LncRNAs Act as a Link between Chronic Liver Disease and Hepatocellular Carcinoma

Kim

Park

Lee

2020

IJMS

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) are emerging as important contributors to the biological processes underlying the pathophysiology of various human diseases, including hepatocellular carcinoma (HCC). However, the involvement of these molecules in chronic liver diseases, such as nonalcoholic fatty liver disease (NAFLD) and viral hepatitis, has only recently been considered in scientific research. While extensive studies on the pathogenesis of the development of HCC from hepatic fibrosis have been conducted, their regulatory molecular mechanisms are still only partially understood. The underlying mechanisms related to lncRNAs leading to HCC from chronic liver diseases and cirrhosis have not yet been entirely elucidated. Therefore, elucidating the functional roles of lncRNAs in chronic liver disease and HCC can contribute to a better understanding of the molecular mechanisms, and may help in developing novel diagnostic biomarkers and therapeutic targets for HCC, as well as in preventing the progression of chronic liver disease to HCC. Here, we comprehensively review and briefly summarize some lncRNAs that participate in both hepatic fibrosis and HCC.

show abstract

Section: Introductionmentioning

confidence: 99%

LncRNAs Act as a Link between Chronic Liver Disease and Hepatocellular Carcinoma

Kim

Park

Lee

2020

IJMS

View full text Add to dashboard Cite

show abstract

“…The diagnosis of an unresectable huge HCC shows a poor prognosis as tumor size is an important prognostic factor for survival outcomes in patients with HCC. 4,18 A multi-modality approach could be considered for better clinical outcomes in this clinical situation, however, there has been no clear evidence supporting the use of combined treatment in patients with huge HCC. Complete uptake of iodized oil is not usually observed even after repeated TACE for huge HCC; [19][20][21][22] therefore, radiotherapy for residual viable HCC after incomplete TACE can be an effective treatment option.…”

Section: Discussionmentioning

confidence: 99%

Combined Transarterial Chemoembolization and External Beam Radiotherapy in a Patient with Recurrent Huge Hepatocellular Carcinoma after Hepatic Resection

Jung

Yoon³

2020

J Liver Cancer

View full text Add to dashboard Cite

The optimal treatment strategy for unresectable huge hepatocellular carcinoma (HCC) is yet to be established. Non-surgical monotherapy demonstrated insufficient oncologic outcomes in previously reported studies. To improve the clinical outcomes of unresectable huge HCC, combined locoregional treatments can be considered in selected cases. Here, we report a case of 58-year-old male patient who was treated with combined transarterial chemoembolization (TACE) and external beam radiotherapy for recurrent HCC after a previous hepatic resection. After combined TACE and radiotherapy for the intrahepatic lesion, two metastases were diagnosed in the pelvic bones and lung; each lesion was successfully treated with salvage radiotherapy. During the long-term follow-up period (around 8 years 7 months after combined TACE and radiotherapy for the recurrent huge HCC), no definite viable tumors were observed in any of the treated liver, bone, and lung lesions.

show abstract

“…Therefore, we evaluated treatment response to DEB-TACE and cTACE in huge HCC patients and discovered that ORR and DCR were higher in DEB-TACE group compared with cTACE group. The possible explanations were: (1) Microspheres had better drug loading and releasing profiles than lipiodol used in cTACE, resulting in As for survival profiles of DEB-TACE and cTACE in HCC patients, discrepancy still exists in different clinical researches. Some studies state that DEB-TACE is better than cTACE in prolonging patients' survival, whereas other voices claim that there is no difference in survival profiles between these two treatments [28][29][30][31].…”

Section: Discussionmentioning

confidence: 99%

“…Hepatocellular carcinoma (HCC) is the most common carcinoma as well as the second cause of cancer-related deaths in China, and huge HCC, accounting for around 20% of HCC cases, is defined as HCC whose nodule size is greater than 10 cm in diameter [1][2][3]. Although the medical treatments for HCC have developed a lot in recent decades, there is still no recognized standard treatment for huge HCC, and the most commonly used curative approach for huge HCC is surgical resection, while due to large nodule size, high risk of tumor rupture, vascular invasion as well as intrahepatic metastasis, the incidence of intraoperative death remains higher and post-operational survival is still worse in huge HCC patients compared to smaller HCC patients [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Comparison of treatment response, survival profiles as well as safety profiles between CalliSpheres® microspheres transarterial chemoembolization and conventional transarterial chemoembolization in huge hepatocellular carcinoma

Duan¹,

Liu²,

Han³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: This study aimed to compare treatment response, survival and safety profiles between drug-eluting beads transarterial chemoembolization (DEB-TACE) with CalliSpheres® microspheres (CSM) and conventional TACE (cTACE) in huge hepatocellular carcinoma (HCC) patients.Methods: 71 patients with huge HCC underwent DEB-TACE or cTACE were consecutively enrolled. Treatment response was assessed at first month (M1), third month (M3) and sixth month (M6) after TACE therapy; progression free survival (PFS) and overall survival (OS) were evaluated; liver function indexes were recorded before TACE operation (M0), at first week (W1), M1 and M6 after TACE therapy; adverse events which occurred after TACE operation were recorded. Results: DEB-TACE presented with higher objective response rate (ORR) and disease control rate (DCR) compared to cTACE. Regarding survival profiles, the short-term mortality rate was lower, and PFS as well as OS were longer in DEB-TACE group compared with cTACE group. Multivariate Cox’s regression further illustrated that DEB-TACE vs cTACE was an independent protective factor for PFS and OS. As for safety profiles, patients’ liver function injury was reduced in DEB-TACE group compared with cTACE group. The incidence of fever was lower and CINV were less severe in DEB-TACE group compared with cTACE group, while no difference in occurrence of liver abscess, increase of ascites or moderate pain between two groups was observed. Conclusion: DEB-TACE with CSM presents with better treatment response, survival profiles as well as safety profiles compared to cTACE in treatment for huge HCC patients.

show abstract

Huge hepatocellular carcinoma greater than 10 cm in diameter worsens prognosis by causing distant recurrence after curative resection

Abstract: Huge HCC (≥10 cm) is an independent risk factor due to a high risk for initial extra-hepatic recurrence. Future systemic adjuvant therapy is needed for these patients. J. Surg. Oncol. 2017;115:324-329. © 2016 Wiley Periodicals, Inc.

Cited by 47 publications

References 36 publications

LncRNAs Act as a Link between Chronic Liver Disease and Hepatocellular Carcinoma

LncRNAs Act as a Link between Chronic Liver Disease and Hepatocellular Carcinoma

Combined Transarterial Chemoembolization and External Beam Radiotherapy in a Patient with Recurrent Huge Hepatocellular Carcinoma after Hepatic Resection

Comparison of treatment response, survival profiles as well as safety profiles between CalliSpheres® microspheres transarterial chemoembolization and conventional transarterial chemoembolization in huge hepatocellular carcinoma

Contact Info

Product

Resources

About